Citation Impact
Citing Papers
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015
2018 Standout
Evidence of Interhospital Transmission of Extended-Spectrum β-Lactam-Resistant Klebsiella pneumoniae in the United States, 1986 to 1993
1997
The Pseudomonas aeruginosa accessory genome elements influence virulence towards Caenorhabditis elegans
2019 StandoutNobel
ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii
1993
Activity of meropenem against imipenem-resistant bacteria and selection in vitro of carbapenem-resistantEnterobacteriaceae
1992
Xanthomonas maltophilia: An Emerging Nosocomial Pathogen
1989
Evolution and spread of SHV extended-spectrum β-lactamases in Gram-negative bacteria
1999
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001
2003
Understanding biofilm resistance to antibacterial agents
2003 Standout
Intracellular pH regulation in heart
2008
Telavancin: A Novel Lipoglycopeptide
2009
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Taking inventory: antibacterial agents currently at or beyond Phase 1
2004
Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum β-lactamases
2001
Molecular mechanisms of antibiotic resistance
2014 Standout
Occurrence of sulfonamide and tetracycline-resistant bacteria and resistance genes in aquaculture environment
2012
Microbial tryptophan catabolites in health and disease
2018 Standout
Molecular Epidemiology of an SHV-5 Extended-Spectrum -Lactamase in Enterobacteriaceae Isolated from Infants in a Neonatal Intensive Care Unit
1995
Origin and impact of plasmid-mediated extended-spectrum beta-lactamases
1994
Engineering and characterization of a superfolder green fluorescent protein
2005 Standout
Ciprofloxacin
1988
Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes
2006
In VitroAntibacterial Activity of the New Quinolone Bay y3118 against Clinical Isolates
1994
A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility
2016 Standout
The “hidden” carbapenemase of Aeromonas hydrophila
1996
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
2011 Standout
The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections
2004
Myocardial ischemia-reperfusion injury: a neglected therapeutic target
2013 Standout
Ciprofloxacin: In Vitro Activity, Mechanism of Action, and Resistance
1988
Na+/h+exchange inhibitors for cardioprotective therapy: progress, problems and prospects
2002
Multiple Antibiotic–Resistant Bacteria in Long‐Term‐Care Facilities: An Emerging Problem in the Practice of Infectious Diseases
2000
Evidence for Direct Regulation of Myocardial Na+/H+ Exchanger Isoform 1 Phosphorylation and Activity by 90-kDa Ribosomal S6 Kinase (RSK): Effects of the Novel and Specific RSK Inhibitor fmk on Responses to α1-Adrenergic Stimulation
2006
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
2008 Standout
Antibacterial resistance worldwide: causes, challenges and responses
2004 Standout
Indole as an intercellular signal in microbial communities
2009
Carbapenemases: a problem in waiting?
2000
Methicillin-Resistant Staphylococcus aureus
1989 Standout
University of California/Davis Interdepartmental Conference on Gram-Negative Septicemia
1991 StandoutNobel
Polymer Therapeutics: Concepts and Applications
2006
Methicillin-Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic, and Therapeutic Odyssey
2005
Pathogenic Escherichia coli
2004 Standout
A hospital outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae investigated by RAPD typing and analysis of the genetics and mechanisms of resistance
1998
Widespread Distribution of Urinary Tract Infections Caused by a Multidrug-ResistantEscherichia coliClonal Group
2001
Type 1 fimbriae and extracellular polysaccharides are preeminent uropathogenic Escherichia coli virulence determinants in the murine urinary tract
2002
Inhibitor-resistant TEM -lactamases: phenotypic, genetic and biochemical characteristics
1999
Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both
1989
Does high level production of SHV-type penicillinase confer resistance to ceftazidime in enterobacteriaceae?
1992
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study
2007
Myocardial Reperfusion Injury
2007 Standout
Crystal structures of the class D β-lactamase OXA-13 in the native form and in complex with meropenem
2001
Comparison of susceptibility to extended-spectrum β-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units
1995
Uncomplicated Urinary Tract Infection
2012 Standout
Sensors and regulators of intracellular pH
2009 Standout
A plastid organelle as a drug target in apicomplexan parasites
1997 StandoutNature
Susceptibility to -lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 -lactamases
1991
Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms
2008
Epidemiology of urinary tract infections
2003
Assessment and Management of Foot Disease in Patients with Diabetes
1994 Standout
Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms
2001
Characterization of an SHV-5 related extended broad-spectrum beta-lactamase in enterobacteriaceae from western australia
1993
Newly documented antimicrobial activity of quinolones
1991
Efflux-mediated antimicrobial resistance
2005
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
In- VitroActivity of Meropenem, a New Carbapenem, Against Imipenem-ResistantPseudomonas aeruginosaandXanthomonas maltophilia
1991
The pros, cons, and many unknowns of probiotics
2019 Standout
CTX-M: changing the face of ESBLs in Europe
2006
An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases
2007 Standout
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Physiology and Pathophysiology of Carnosine
2013 Standout
In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii
1984
Evaluation of a New Etest for Detecting Metallo-β-Lactamases in Routine Clinical Testing
2002
Fluorine in medicinal chemistry
2007 Standout
Acinetobacter baumannii : Emergence of a Successful Pathogen
2008 Standout
Pseudomonas aeruginosa Reveals High Intrinsic Resistance to Penem Antibiotics: Penem Resistance Mechanisms and Their Interplay
2001
Gut Microbiota in Health and Disease
2010 Standout
23S rRNA base pair 2057–2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A→G
2005 StandoutNobel
Trends in Antibiotic Resistance Genes Occurrence in the Haihe River, China
2010
Epidemiology of Extended-Spectrum β-Lactamase-Producing Enterobacter Isolates in a Spanish Hospital during a 12-Year Period
2002
Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 beta-lactamase and which were isolated in 14 French hospitals
1994
In Vitro Activity of Telavancin in Combination with Colistin versus Gram-Negative Bacterial Pathogens
2012
New insight into the mode of action of vancomycin dimers in bacterial cell wall synthesis
2011
The Aminoglycosides
1999
Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications
2019 Standout
Carbapenemases: the Versatile β-Lactamases
2007 Standout
Catalytic properties of class A β-lactamases: efficiency and diversity
1998
Novel transferable extended-spectrum β-lactamase (SHV-6) fromKlebsiella pneumoniaeconferring selective resistance to ceftazidime
1991
Relation of structural properties of beta-lactam antibiotics to antibacterial activity
1985
High-Level Expression of Chromosomally Encoded SHV-1 β-Lactamase and an Outer Membrane Protein Change Confer Resistance to Ceftazidime and Piperacillin- Tazobactam in a Clinical Isolate of Klebsiella pneumoniae
2000
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
2003 Standout
β -Lactamases: which ones are clinically important?
2000
A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy
1994
Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks
1985
Dynamic Kinetic Resolution Process Employing Haloalkane Dehalogenase
2011 StandoutNobel
Inhibitor-resistant TEM (IRT) beta-lactamases with different substitutions at position 244
1997
Properties of the beta-lactamase (penicillinase) produced byLevinea malonatica
1980
Evidence of Interhospital Transmission of Extended-Spectrum β-Lactam-Resistant Klebsiella pneumoniae in the United States, 1986 to 1993
1997
Regulation of ompF porin expression by salicylate in Escherichia coli
1991
Reduced Reperfusion–Induced Ins(1,4,5)P3Generation and Arrhythmias in Hearts Expressing Constitutively Active α1B-Adrenergic Receptors
1998
Characterization of a Pseudomonas aeruginosa Efflux Pump Contributing to Aminoglycoside Impermeability
1999
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Mechanisms of Decreased Susceptibility to Cefpodoxime in Escherichia coli
2002
Functional Consequences of Altering Myocardial Adrenergic Receptor Signaling
2000 StandoutNobel
Carbapenem-hydrolyzing beta-lactamases
1997
A Novel Complex Mutant β-Lactamase, TEM-68, Identified in a Klebsiella pneumoniae Isolate from an Outbreak of Extended-Spectrum β-Lactamase-Producing Klebsiellae
2000
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
2005 Standout
Novel Fluorogenic Substrates for Imaging β-Lactamase Gene Expression
2003 StandoutNobel
More extended-spectrum beta-lactamases
1991
Sampling the Antibiotic Resistome
2006 StandoutScience
Decreased outer membrane permeability in imipenem-resistant mutants of Pseudomonas aeruginosa
1989
High Rate of Fatal Cases of Pediatric Septicemia Caused by Gram-Negative Bacteria with Extended-Spectrum Beta-Lactamases in Dar es Salaam, Tanzania
2005
Daptomycin Is Highly Efficacious against Penicillin-Resistant and Penicillin- and Quinolone-Resistant Pneumococci in Experimental Meningitis
2004
Extended-Spectrum β-Lactamases: a Clinical Update
2005 Standout
Comprehensive Evaluation of Antibiotics Emission and Fate in the River Basins of China: Source Analysis, Multimedia Modeling, and Linkage to Bacterial Resistance
2015 Standout
Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii
1995
Use of Microdilution Panels with and without β-Lactamase Inhibitors as a Phenotypic Test for β-Lactamase Production among Escherichia coli , Klebsiella spp., Enterobacter spp., Citrobacter freundii , and Serratia marcescens
1999
Selection and Characterization of β-Lactam–β-Lactamase Inactivator-Resistant Mutants following PCR Mutagenesis of the TEM-1 β-Lactamase Gene
1998
Biochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli
1993
Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection
1984
Biochemical properties of inducible beta-lactamases produced from Xanthomonas maltophilia
1994
Occurrence of Extended-Spectrum β-Lactamases in Members of the Genus Shigella in the Republic of Korea
2004
Virulence factors in Escherichia coli urinary tract infection
1991
Reengineering Antibiotics to Combat Bacterial Resistance: Click Chemistry [1,2,3]‐Triazole Vancomycin Dimers with Potent Activity against MRSA and VRE
2016 StandoutNobel
Bile Salt Hydrolase Activity in Probiotics
2006
High specificity of cphA-encoded metallo-beta-lactamase from Aeromonas hydrophila AE036 for carbapenems and its contribution to beta-lactam resistance
1993
Ceftazidime-Resistant Enterobacteriaceae Isolates from Three Polish Hospitals: Identification of Three Novel TEM- and SHV-5-Type Extended-Spectrum β-Lactamases
1998
Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase
1996
Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer
1990
The Crisis in Antibiotic Resistance
1992 StandoutScience
Purification and characterization of inducible beta-lactamases in Aeromonas spp
1990
Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 beta- lactamase: parallel outbreaks due to multiple plasmid transfer
1996
A secondary drug resistance mutation of TEM-1 β-lactamase that suppresses misfolding and aggregation
2000
A functional classification scheme for beta-lactamases and its correlation with molecular structure
1995 Standout
Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates
1990
Mutant TEM β-Lactamase Producing Resistance to Ceftazidime, Ampicillins, and β-Lactamase Inhibitors
2002
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
The Aeromonas hydrophila cphA gene: molecular heterogeneity among class B metallo-beta-lactamases
1991
Construction and Characterization of Mutants of the TEM-1 β-Lactamase Containing Amino Acid Substitutions Associated with both Extended-Spectrum Resistance and Resistance to β-Lactamase Inhibitors
1999
Interactions between Biocide Cationic Agents and Bacterial Biofilms
2002
ANTIBIOTICS TARGETING RIBOSOMES: Resistance, Selectivity, Synergism, and Cellular Regulation
2005 StandoutNobel
Origins and Evolution of Antibiotic Resistance
2010 Standout
Plasmid-Determined AmpC-Type β-Lactamases
2002
Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001
2003
Conjugative Resistance to Tazobactam Plus Piperacillin Among Extended-spectrum Beta-lactamase-producing Nosocomial Klebsiella pneumoniae
2001
Three Cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China
2002
Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia
1998 Standout
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro
1985
Polymere Therapeutika: Konzepte und Anwendungen
2006
Rapid Detection and Evaluation of Clinical Characteristics of Emerging Multiple-Drug-Resistant Gram-Negative Rods Carrying the Metallo-β-Lactamase Gene bla IMP
1998
A Large Toxin from Pathogenic Escherichia coli Strains That Inhibits Lymphocyte Activation
2000
Development of the quinolones
2003
Biochemical characterization of the carbapenem-hydrolyzing β-lactamase AsbM1 fromAeromonas sobriaAER 14M: a member of a novel subgroup of metallo-β-lactamases
1996
Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae Strains Causing Nosocomial Outbreaks of Infection in the United Kingdom
1998
Works of Anna King being referenced
Sensitivity of Citrobacter freundii and Citrobacter koseri to cephalosporins and penicillins
1974
Ceftazidime: in-vitro antibacterial activity and susceptibility to -lactamases compared with that of cefotaxime, moxalactam and other -lactam antibiotics
1981
Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom
1989
Prevalence of resistance to β-lactam antibiotics in Escherichia coli isolated from blood from 1969–1991
1992
A comparison of the in-vitro activity of clarithromycin, a new macrolide antibiotic, with erythromycin and other oral agents
1991
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria
2004
Comparative Activity of the 4-Quinolones
1988
Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin
2002
The in-vitro activity of tosnfloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin
1991
Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis
2000
The antibiotic sensitivity of bacteria isolated from the blood of patients in St Thomas' Hospital, 1969-1988
1990
Antibiotic sensitivity of theBacteroides fragilis group in Europe
1992
The in-vitro activity of temafloxacin compared with other antimicrobial agents
1991
EPIDEMIC MULTIRESISTANT ESCHERICHIA COLI INFECTION IN WEST LAMBETH HEALTH DISTRICT
1988
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates
2001
The in-vitro activity of PD127,391, a new quinolone
1988
Importation of organisms producing broad-spectrum SHV-group β-lactamases into the United Kingdom
1990
Incidence and Mechanisms of Resistance to the Combination of Amoxicillin and Clavulanic Acid in Escherichia coli
1998
The in nitro antibacterial activity of cefotaxime compared with that of cefuroxime and cefoxitin
1980
β-Lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila
1986
Hyperproduction of TEM-1 beta-lactamase in clinical isolates ofEscherichia coliserotype O15
1990
Thrombin Activates the Sarcolemmal Na+-H+Exchanger
1996
The comparative in-vitro activity of eight newer quinolones and nalidixic acid
1986
Sulfonamide Resistance in Haemophilus influenzae Mediated by Acquisition of sul2 or a Short Insertion in Chromosomal folP
2002
N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics
1981
Recommendations for susceptibility tests on fastidious organisms and those requiring special handling
2001
Prevalence and mechanisms of aminoglycoside resistance: A ten-year study
1986
Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli
1995
The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin
1985
SQ 26,776: in-vitro antibacterial activity and susceptibility to -lactamases
1981
Sch 29482: in-vitro antibacterial activity and susceptibility to -lactamases
1982
The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid
1984
In vitro antibacterial activity of norfloxacin (MK-0366)
1982
The comparative in-vitro activity of pefloxacin
1986